Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Essure birth control

This article was originally published in The Gray Sheet

Executive Summary

FDA's Obstetrics and Gynecology Devices Advisory panel will review one-year data on 400 patients treated with Conceptus' non-incisional permanent birth control device at its July 22-23 meeting. Submitted April 19, the Essure PMA was granted expedited review, and the device could be approved and on the market by the end of 2002, Conceptus notes (1"The Gray Sheet" March 25, 2002, p. 21). In clinical trials, the device has shown 100% effectiveness in preventing pregnancy, leading to a projected one-year efficacy rate of 99.8%, the firm reports...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT016615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel